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Abstract
Adisintegrins andmetalloproteinases with thrombospondinmotifs (ADAMTS) familymembers have been reported
dysregulated in various cancers. Through reﬁning a loss of heterozygosity locus at 11q25 by array-CGH, we identiﬁed
ADAMTS8 as a novel candidate tumor suppressor gene. Although ADAMTS8 downregulation has been reported in
several tumors, its biologic function and underlying mechanism remain largely unknown. Here, we found that
ADAMTS8 is broadly expressed in normal tissues but frequently downregulated or silenced by promoter methylation
in common carcinoma cell lines, including nasopharyngeal, esophageal squamous cell, gastric, and colorectal carcino-
mas. Pharmacologic or genetic demethylation restored ADAMTS8 expression, indicating that promoter methylation
mediates its silencing. Aberrant methylation of ADAMTS8 was also detected in several types of primary tumors but
rarely in normal tissues. Further functional studies showed that restoring ADAMTS8 expression suppressed tumor cell
clonogenicity through inducing apoptosis. ADAMTS8 as a secreted protease inhibited epidermal growth factor receptor
(EGFR) signaling along with decreased levels of phosphorylated MEK and ERK. We further found that ADAMTS8
disrupted actin stress ﬁber organization and inhibited tumor cell motility. Thus, our data demonstrate that ADAMTS8
metalloprotease acts as a functional tumor suppressor through antagonizing EGFR–MEK–ERK signaling, in addition
to its previously reported anti-angiogenesis function, and is frequently methylated in common tumors.
Implications: This study uncovers the tumor suppressive function of ADAMTS8, one of the ADAMTS family
members, and its frequent methylation in certain tumors could be developed as a potential biomarker.Mol Cancer
Res; 12(2); 228–38. 2013 AACR.
Introduction
Metalloproteinases are initially regarded to facilitate tumor
progression by promoting angiogenesis and metastatic dis-
semination of cancer cells through extracellular matrix
(ECM) degradation (1). However, this concept is challenged
by recent ﬁndings of several members showing to possess
tumor suppressive functions (2–6). A disintegrins andmetal-
loproteinases with thrombospondin motifs (ADAMTS), a
family of extracellular metalloproteases, is structurally and
functionally similar to matrix metalloproteinases (MMP)
and ADAMs (7).Unlike ADAMsmainly as trans-membrane
proteins, ADAMTSs are secreted proteinases binding to
ECM (8). Dysregulated expression of ADAMTSs, such as
ADAMTS1 (2), ADAMTS8, ADAMTS9 (5), ADAMTS12
(3), ADAMTS15 (4), ADAMTS18 (6), and ADAMTS20
(9, 10), have been detected in diverse types of malignancies
including lung, brain, breast, gastric, prostate, pancreatic
cancers, and glioblastoma (8). Various ADAMTSs have been
shown to regulate cell proliferation, adhesion, migration,
angiogenesis, and intracellular signaling (8, 11), thus
involved in multiple tumor pathogenesis (1, 6).
ADAMTS8 is 1 of the 3 ADAMTS members with anti-
angiogenic property, indicating its potential as a tumor
suppressor (5, 12, 13). Downregulation of ADAMTS8 has
been found in some tumors, such as brain tumors (14),
breast carcinoma (9), non–small cell lung carcinoma (15),
head and neck squamous cell carcinoma (16), and pancreatic
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cancer (17), whereas its expression in other common solid
tumors including nasopharyngeal (NPC), esophageal squa-
mous cell (ESCC), gastric, colorectal (CRC), renal (RCC),
and cervical carcinomas remains unclear.
Genetic and epigenetic alterations especially promoter
methylation and histone modiﬁcations play a crucial role
in tumor initiation and progression, although leading to
activation of oncogene and inactivation of tumor suppressor
gene (TSG). Promoter methylation of ADAMTS8 has been
detected in brain tumors (14), non–small cell lung carcino-
ma (15) and thyroid cancer (18), which also could serve as
one of the signatures for primary thyroid cancer (18),
suggesting that epigenetic silencing of ADAMTS8 may be
involved in tumorigenesis. However, its tumor suppressive
functions and underlying mechanisms in tumor pathogen-
esis are largely unknown.
Through reﬁning an LOH locus at 11q25 by 1-Mb
array comparative genomic hybridization (array-CGH)
and expression proﬁling of the affected genes, we iden-
tiﬁed ADAMTS8 as a candidate TSG. In this study, we
examined the expression and methylation of ADAMTS8
in common solid carcinomas and further explored its
tumor suppressive functions and relevant mechanisms in
tumorigenesis.
Materials and Methods
Cell lines, tumors, and normal tissue samples
Multiple cell lines of NPC, ESCC, gastric, and CRC,
hepatocellular (HCC), lung, breast, RCC, and cervical
carcinomas and several immortalized normal epithelial
cell lines were used (19, 20). Cell lines were obtained
either from the American Type Culture Collection or our
collaborators. HCT116-DKO cell line with double
knockout of DNA methyltransferases DNMT1 and
DNMT3B was also used (gifts of Bert Vogelstein, Johns
Hopkins University, Baltimore, MD). Cell lines were
treated with 10 mmol/L 5-aza-20-deoxycytidine (Aza;
Sigma-Aldrich) for 3 days or further treated with 100
nmol/L trichostatin A (TSA; Cayman Chemical Co.) for
additional 16 hours as described previously (21).
Human normal adult and fetal tissue RNA samples were
purchased commercially (Stratagene or Millipore-Chemi-
con; refs. 20 and 22). Genomic DNA samples of normal
nasopharyngeal and gastric tissues, as well as primary tumor
tissues of nasopharyngeal carcinoma, gastric cancer, and
colorectal carcinoma, have been described previously
(19, 23–25). Clinical information was available for the
majority of gastric cancer samples.
Semiquantitative reverse transcription-PCR and
quantitative real-time RT-PCR
Semiquantitative reverse transcription-PCR (RT-PCR)
and quantitative real-time PCR (qPCR) were performed
as described previously (21, 26). RT-PCR was performed
for 32 cycles using Go-Taq Flexi DNA polymerase (Pro-
mega). SYBR Green master mix (Applied Biosystems)
was used for real-time PCR analysis. GAPDH was used as
an internal control. Primers are listed in Supplementary
Table S1.
Methylation-speciﬁc PCR and bisulﬁte genomic
sequencing
Bisulﬁte treatment of genomic DNA, methylation-spe-
ciﬁc PCR (MSP), and bisulﬁte genomic sequencing (BGS)
were performed as described previously (22, 27). Brieﬂy, 1
mm of bisulﬁte-treated DNA (around 50 ng) was used for
MSP ampliﬁed by using 0.625 U of AmpliTaq Gold
polymerase (Applied Biosystems) with 2.0 mmol/L
MgCl2 and 0.2 mmol/L dNTP in a 25 mL reaction volume.
PCR was performed at 95C for 10 minutes, followed by 40
cycles consisting of 94C for 30 seconds, annealing at 60C
(methylation detection) or 58C (unmethylation detection)
for 30 seconds, and 72C for 30 seconds, and a ﬁnal
extension at 72C for 5 minutes. PCR products were
analyzed on a 1.8% agarose gel. For BGS, bisulﬁte-treated
DNA was ampliﬁed for using BGS primers, and the PCR
products were cloned into the PCR4-TOPO vector (Invi-
trogen). In all, 6 to 10 colonies were randomly chosen and
sequenced. MSP and BGS primers are shown in Supple-
mentary Table S1.
ADAMTS8 deletion analysis
Homozygous deletion of ADAMTS8 coding exon 1 and
exon 2was examined usingmultiplex genomic DNAPCR as
previously described (20, 23). A 301-bp fragment and a 349-
bp fragment of the ADAMTS8 were ampliﬁed along with a
134-bp fragment of APRT as internal control. The PCR was
performed in a 12.5 mL reaction mixture consisting of 0.4
mmol/L of primers located onADAMTS8 exon 1 and exon 2,
0.2 mmol/L of APRT primers, 0.2 mmol/L of dNTP, 2.0
mmol/L of MgCl2, 1 PCR Buffer II, 0.3125 U of Ampli-
Taq Gold (Applied Biosystems), and 50 ng of template
DNA. PCR was conducted as 95C for 10 minutes, then 35
cycles (94C, 30 seconds; 55C, 30 seconds; 72C, 30
seconds), followed by 72C for 10 minutes. PCR products
were analyzed on 1.8% agarose gels. Primers are listed in
Supplementary Table S1.
Construction of ADAMTS8-expressing vectors
The full-length open reading frame of ADAMTS8 was
cloned from normal adult larynx cDNA library into pCR4-
TOPO vector (Invitrogen). A Flag tag was fused to the
C-terminal of ADAMTS8 by PCR ampliﬁcation and
the coding sequence of ADAMTS8-Flag was subcloned
into pcDNA3.1(þ) with BamHI and XhoI to generate
pcDNA3.1(þ)-ADAMTS8-Flag. ADAMTS8 was further
subcloned into the pEGFP-N1 vector to generate a pEGFP-
N1-ADAMTS8. All PCR reactions were performed with
AccuPrime polymerase (Invitrogen) and all cloned frag-
ments were validated by sequencing.
Immunoﬂuorescence
Cells grown on coverslips were stained by immunoﬂuo-
rescence as described previously (19, 20). In brief, HONE1
or KYSE150 cells were transfected with pcDNA3.1
Methylation of ADAMTS8 in Carcinomas
www.aacrjournals.org Mol Cancer Res; 12(2) February 2014 229
on November 24, 2015. © 2014 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Published OnlineFirst November 1, 2013; DOI: 10.1158/1541-7786.MCR-13-0195 
(þ)-ADAMTS8-Flag or pEGFP-N1-ADAMTS8 plasmid.
At 48-hour posttransfection, cells were ﬁxed with 4% (w/v)
paraformaldehyde before staining with primary and FITC-
conjugated secondary antibodies (F313; Dako) for half an
hour at 37C. For actin staining, cells were stained with
rhodamine-conjugated phalloidin for 1 hour at 37C. Cells
were counterstained with 40,6-diamidino-2-phenylindole
(DAPI) before analysis using Olympus BX51 microscope
(OlympusCorporation) and Leica TCS SP5 confocalmicro-
scope (Leica Microsystems CMS GmbH).
Colony formation assay
Clonogenicity was determined by measuring colonies
growing in monolayer culture as described previously
(6, 21). HONE1 and KYSE150 cells (1  105 per well)
were seeded in a 12-well plate and were transiently trans-
fected with pcDNA3.1(þ)-ADAMTS8-Flag plasmid or the
pcDNA3.1 vector alone, using FuGENE 6 (Roche). At 48-
hours posttransfection, cells were collected and plated at
appropriate density in a 6-well plate underG418 (0.4mg/mL)
selection for 2 to 3 weeks. Cell colonies were ﬁxed and
stained with Gentian Violet (ICM Pharma) before counting
of surviving colonies (>50 cells per colony). Statistical
analysis was performed with Student t test, P < 0.05 was
considered as statistically signiﬁcant difference.
Cell-proliferation assay
MTS (Promega) assay was performed according to the
manufacturer's instruction. Cells were seeded in 96-well
plates at a density of 1 to 2 103, 15 mLMTS solution was
added into each well at indicated time points and then
incubated for 3 hours at 37C. Effect of cell number on
absorbance at 490 nm was measured. The experiments were
performed in triplicate and repeated 3 times.
Apoptosis assay
HONE1 and KYSE150 cells were seeded on glass
coverslips and ﬁxed in 4% paraformaldehyde. Cells were
permeabilized with 0.1% Triton X-100 in PBS for 5
minutes on ice. Apoptoic cells with strand breaks in DNA
were stained using the In Situ Cell Death Detection Kit,
Fluorescein (Roche) according to Manufacturer's proto-
col. The labeling reaction was performed by incubating
each sample with terminal deoxynucleotidyl transferase–
mediated dUTP nick end labeling (TUNEL) reaction
mixture containing terminal deoxynucleotidyl transferase
and ﬂuorescein-labeled dUTP at 37C for 1 hour. DAPI
was used to stain total nuclei. Coverslips were mounted on
glass slides and analyzed under a ﬂuorescence microscope.
Apoptotic cells with condensed or fragmented nuclei were
also examined by DAPI staining.
Western blot analysis
HONE1 and KYSE150 cells were transiently transfected
with pcDNA3.1(þ)-ADAMTS8-Flag plasmid or the
pcDNA3.1 vector alone using FuGENE 6 (Roche). At
48-hour posttransfection, cells were harvested and lysed in
lysis buffer [10 mmol/L Tris-HCl (pH 7.4), 1% SDS, 10%
glycerol, 5 mmol/L MgCl2, 1 mmol/L phenylmethylsulfo-
nyl ﬂuoride, 1 mmol/L sodium orthovandate, 5 mg/mL
leupeptin, and 21 mg/mL aprotinin]. Protein samples were
incubated for 30 minutes on ice and followed by centrifu-
gation to remove cell debris. Supernatant containing 30 mg
of total protein lysate from each sample was subjected to
SDS-PAGE and transferred onto a polyvinylidene diﬂuoride
membranes which were probed with anti-MEK1/2, anti-
ERK1/2, anti-phospho-MEK1/2 (Ser217/Ser221), anti-phos-
pho-ERK1/2 (Thr202/Tyr204; Cell Signaling Technology);
anti-epidermal growth factor receptor (EGFR; BD Trans-
duction Laboratories); anti-phosphor-EGFR (Tyr1086; Invi-
trogen); anti-Flag (Sigma-Aldrich), or anti-tubulin (Lab
Vision Corporation) primary antibodies. Protein bands were
visualized by enhanced chemiluminescence detection system
(GE Healthcare Bio-Sciences).
Conditioned medium
Conditioned medium containing secreted ADAMTS8
was collected from pcDNA3.1(þ)-ADAMTS8-Flag-trans-
fected KYSE150 and HONE1 cells cultured in RPMI 1640
with 3% FBS for indicated times after centrifuged at 1,000 g
for 30 minutes. KYSE150 cells were treated with condi-
tioned medium containing ADAMTS8 for 24 hours and
collected for further study.
Luciferase reporter assay
Reporter activity of the serum response element (SRE)-
luc, AP-1 plasmids (Stratagene) was determined in HONE1
and KYSE150 cells as described previously (19, 28). Sub-
conﬂuent cells in 24-well plates were transiently cotrans-
fected with pSRE-luc, pcDNA3.1(þ)-ADAMTS8-Flag and
pRL-SV40. After 48 hours, cells were harvested for luciferase
activity measurement using Dual-Luciferase Reporter Assay
System (Promega). Activity of the ﬁreﬂy luciferase reporter
(SRE)-luc and AP-1-luc were normalized with the activity of
the renilla luciferase pRL-SV40 as an internal control to
correct the differences in transfection efﬁciency. Each exper-
iment was performed in triplicates and was repeated 3 times.
Wound healing assay
Cell motility of HONE1 and KYSE150 cells transfected
with pEGFP-N1-ADAMTS8 or control pEGFP-N1 vector
was assessed using a scratch wound assay. Cells were cultured
in 6-well dishes until conﬂuent before using sterile tips to
scratch a wound. After rinsing with PBS, cells were incu-
bated with fresh medium and images of wounds were taken
under a phase contrast microscope at 0, 24, and 48 hours
after wounding. The experiments were performed in
triplicate.
Results
Identiﬁcation of ADAMTS8 as a downregulated gene at
11q24.2-25
A deletion at 11q24.2-25 was frequently detected in a
panel of NPC and ESCC tumor cell lines by 1-Mb aCGH
(Fig. 1A). Expression proﬁling of all the 34 genes within this
deletion was further analyzed by semiquantitative RT-PCR
Choi et al.
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(data not shown). ADAMTS8 was found to be silenced in
virtually all the NPC cell lines studied, but readily expressed
in immortalized normal nasopharyngeal epithelial cell line
and normal tissues of larynx and trachea as well as other
normal adult and fetal tissues with varying expression levels
except for bone marrow (Figs. 1B and 2A). In addition,
frequent silencing or downregulation of ADAMTS8 was
also observed in multiple other carcinoma cell lines, includ-
ing 6 of 6 NPC (100%), 12 of 16 ESCC (75%), 14 of 16
gastric (88%) and 4 of 5 CRC (80%), 11 of 13HCC (85%),
3 of 5 Lung (60%), 7 of 9 breast (78%), 5 of 7 RCC (71%),
and 3 of 4 cervical (75%) cancers (Fig. 2A and B and
Supplementary Fig. S1 and Table S2). We further assessed
ADAMTS8 expression in representative nasopharyngeal,
esophageal, and colon carcinoma cell lines by qPCR. As
expected, we conﬁrmed that ADAMTS8 was frequently
downregulated in tumor cell lines, but readily expressed in
normal tissues, consistent with the semiquantitative
RT-PCR results. These data suggest that ADAMTS8 is a
candidate tumor suppressor.
Promoter methylation of ADAMTS8 contributes to its
silencing
To investigate the mechanism of ADAMTS8 downregu-
lation in tumors, we ﬁrst evaluated its genetic alterations.
Multiplex differential genomic DNA-PCR for ADAMTS8
and APRT was performed to detect ADAMTS8 deletion in a
region spanning exon 1 and exon 2. Results showed that
homozygous or hemizygous deletion was detected in several
tumor cell lines with or without silenced ADAMTS8 (Sup-
plementary Fig. S2), suggesting that genetic alterations are
one of the mechanisms for ADAMTS8 silencing. Moreover,
analysis of ADAMTS8 mutations using online database
(Wellcome Trust Cancer Genome Project, http://www.
sanger.ac.uk) revealed only one missense somatic mutation
of ADAMTS8 reported in glioblastoma (29), indicating that
its genetic sequence mutation is uncommon in tumors.
A typical CpG Island (CGI) spanning the exon 1 of
ADAMTS8 is predicted by CpG Island Searcher (http://
cpgislands.usc.edu/; Fig. 1A). Thus, promoter methylation
ofADAMTS8was further examined byMSP and found to be
frequently detected in multiple carcinoma cell lines, includ-
ing 100% of NPC, 44% of ESCC, 56% of gastric, 78% of
CRC, 8% of HCC, 22% of breast, 43% of RCC, and 29%
of cervical cancers (Fig. 2A and Supplementary Fig. S1 and
Table S2), but seldom in lung cancer cell lines and not in
normal epithelial cell lines (Fig. 2A). MSP results were
further conﬁrmed using high-resolution BGS of 63 CpG
sites spanning the ADAMTS8CGI (Fig. 2B). We also noted
that no methylation was detected in several cell lines with
silenced or reduced ADAMTS8, including ESCC cell lines:
EC1, EC18, HKESC1, HKESC2, KYSE140, KYSE180,
KYSE510, and KYSE520 and gastric tumor cell lines:
SNU16, YCC1, YCC7, and YCC16, indicating that other
regulatory mechanisms such as histone modiﬁcations might
also be involved.
We further found that ADAMTS8 expression was
restored after treatment with DNA methyltransferase
inhibitor Aza, or in combination with TSA, accompanied
by concomitant decrease of methylated alleles and
Figure 1. ADAMTS8 is a candidate
TSG located at 11q25. A,
schematic diagram showing the
relative gene locus of ADAMTS8 in
11q25 and the exon/intron
structure of its transcript. The
position of ADAMTS8 in
chromosome 11 is labeled
according to Ensemble
(http://www.ensembl.org/). The
forward and reverse RT-PCR
primers are indicated with arrows.
Other genes located adjacent to
the ADAMTS8 locus are also
shown. Structure of the predicted
CGI spanning ADAMTS8 promoter
and exon 1. Each vertical line
represents one CpG site.
Respective positions of MSP and
BGS primers, and the region
analyzed by BGS are indicated by
arrows. B, semiquantitative
RT-PCR shows ADAMTS8 is
broadly expressed in normal adult
tissues and fetal tissues except for
bone marrow, with GAPDH as an
internal control. Sk. M, skeletal
muscle; B.M., bone marrow;
L.N., lymph node.
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increased unmethylated alleles in silenced tumor cells (Fig.
3A and C). Reactivation of ADAMTS8 and complete
demethylation were also observed in a genetic demethyl-
ation model using colorectal cell line (HCT116) with
genetic double knockout of both DNA methyltransferase
DNMT1 and DNMT3B (DKO; Fig. 3B and C). These
results suggest that ADAMTS8 is an epigenetic-regulated
TSG, and promoter methylation is a major mechanism
mediating ADAMTS8 silencing in tumors.
Frequent ADAMTS8 methylation detected in primary
carcinomas
We next examined ADAMTS8 methylation in primary
tumors. ADAMTS8 methylation was detected in 88% (36/
41) of primary NPC, 58% (69/119) of gastric, 27% (3/11)
of CRC, 22% (8/36) of ESCC, and 6% (3/47) of HCC
tumor samples (Fig. 3E and Supplementary Table S2), but
rarely observed in normal nasopharyngeal tissues (2/11,
18%), and normal gastric tissues (3/18, 17%; Fig. 3D and
Supplementary Table S2). Thus, ADAMTS8methylation is
frequent during tumor pathogenesis.
Although the frequency of ADAMTS8 methylation in
gastric cancer was high, further investigation on patients
with gastric cancer showed no correlations between the
ADAMTS8 methylation status and clinical parameters
including gender, Helicobacter pylori infection, TNM
stage, Lauren type, and tumor differentiation (data not
shown).
ADAMTS8 is a secreted protease inhibiting tumor cell
clonogenicity by inducing apoptosis
ADAMTS8 is a secreted protease with a signal peptide at
its N-terminus according to bioinformatics analysis (pTAR-
GET, http://bioapps.rit.albany.edu/; Fig. 4A). We next
Figure 2. Epigenetic inactivation of
ADAMTS8 in multiple tumor cell
lines. A, analyses of ADAMTS8
expression and promoter
methylation in tumor cell lines and
normal controls. Immortalized




ESCC, esophageal squamous cell
carcinoma; CRC, colorectal
carcinoma; Ca, carcinoma. B,
ADAMTS8 expression was
detected in representative tumor
cell lines and normal tissues by
quantitative RT-PCR. The
expression level of each sample
was normalized to internal control
GAPDH. Fold change ofADAMTS8
expression was calculated relative
to that of normal tissue. C,
representative BGS analyses of
ADAMTS8 promotermethylation in
tumor cells and immortalized
normal epithelial cells. The
ADAMTS8 transcription start site is
indicated with a bent arrow.
Circles, CpG sites analyzed; row of
circles, an individual promoter
allele that was cloned, randomly
selected, and sequenced; ﬁlled
circle, methylated CpG site; open
circle, unmethylated CpG site.
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selected NPC cell line HONE1 and ESCC cell line
KYSE150 with silenced and methylated ADAMTS8 as
tumor model for following functional and mechanical
studies. Subcellular localization of ADAMTS8 by confocal
microscopy showed that ADAMTS8 was mainly localized
to the cell membrane (Fig. 4B).
Culturing media from ADAMTS8-transfected KYSE150
cells and HONE1 cells were collected and subjected to
TCA protein precipitation for the detection of ADAMTS8
expression by Western blot analysis. ADAMTS8 protein
was detected in both the medium and cell lysates of the
transfected KYSE150 cells, with much higher expression
in the medium (Fig. 4C). We also examined ADAMTS8
expression in the medium of ADAMTS8-transfected
HONE1 cells collected at 24, 48, and 72 hours, which
all showed good growth status as measured by cell-prolif-
eration assay (Supplementary Fig. S3A). We found that
ADAMTS8 protein level was gradually decreased in a
time-dependent manner, with no expression of a-tubulin
detected, a marker of total cell lysate (Supplementary
Fig. S3B). These results reveal that ADAMTS8 could be
secreted into the culturing media, thus as a secreted
protease.
We further evaluated the impact ofADAMTS8 expression
on growth inhibition and apoptosis of tumor cells. Ectopic
expression of ADAMTS8 in HONE1 and KYSE150 cells
resulted in signiﬁcant reduction of colony numbers, com-
pared with controls (Fig. 4D; P < 0.05). As reduction of
tumor cell clonogenicity could be attributed to the induction
of apoptosis (30), TUNEL assay was performed, increased
TUNEL-positive cells were observed in ADAMTS8 trans-
fected-KYSE150 andHONE1 cells, together with increased
apoptotic marker cleaved PARP (Fig. 4E). In addition,
ADAMTS8-expressing HONE1 and KYSE150 cells under-
went obvious cell shrinkage, DNA condensation, and frag-
mentation, which are distinct hallmarks of apoptosis (Sup-
plementary Fig. S3C and S3D). These data demonstrate that
ADAMTS8 exerts tumor suppressive function through
inducing apoptosis and inhibiting cell growth.
ADAMTS8 negatively modulates the EGFR–MEK–ERK
signaling pathway
As metalloproteases have been shown involved in tumor-
igenesis through regulating EGFR signaling (31, 32), we
investigated the impact of ADAMTS8 on the EGFR sig-
naling pathway. Culturing medium from KYSE150 cells
Figure 3. Reactivation of ADAMTS8
by pharmacologic and genetic
demethylation. A, restoration of
ADAMTS8 expression by
pharmacologic demethylation
using Aza (A) and TSA (T). B,
genetic demethylation also
activated ADAMTS8 expression in
HCT116 cell line with double
knockout of DNMT1 and DNMT 3B
(DKO). ADAMTS8mRNA level was
measure by semiquantitative
RT-PCR, and itsmethylation status
was detected by MSP. C, detailed
BGS analysis conﬁrmed promoter
demethylation of ADAMTS8 with
pharmacologic and genetic
demethylation. The ADAMTS8
transcription start site is indicated
using a bent arrow. Circles, CpG
sites analyzed; row of circles, an
individual promoter allele that was
cloned, randomly selected, and
sequenced; ﬁlled circle,
methylated CpG site; open circle,
unmethylated CpG. D, E,
representative analyses of
ADAMTS8 methylation in certain
primary tumors and normal tissues
by MSP. M, methylated;
U, unmethylated; NPC,
nasopharyngeal carcinoma;
GsCa, gastric carcinoma; CRC,
colorectal carcinoma.
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transfected with ADAMTS8 was collected as conditioned
medium, and conditioned medium from empty vector-
transfected cells was used as control. We found decreased
phosphorylation of EGFR in cells treated with KYSE150-
transfected ADAMTS8 conditioned medium for 24 hours,
with little change of total EGFR expression. Similar inhib-
itory effects were also observed in the total cell lysate from
transfected cells (Fig. 5A).
We further examined the effects of ADAMTS8 expres-
sion on some downstream effectors of EGFR, such as
MEK-ERK signaling. Results showed that ectopic expres-
sion of ADAMTS8 signiﬁcantly reduced phosphorylation
of MEK and ERK, with no effect on the total level of ERK
(Fig. 5B). SRE and AP-1 luciferase reporter assays were
further used to measure the modulation of MAPK sig-
naling by ADAMTS8. In agreement with the inhibitory
effect of ADAMTS8 on MEK and ERK phosphorylation,
transcriptional activities of SRE and AP-1 reporters were
signiﬁcantly decreased in ADAMTS8-expressing HONE1
and KYSE150 cells (P < 0.05; Fig. 5C and D). These data
indicate that ADAMTS8 indeed negatively regulates
EGFR–MEK–ERK signaling.
Figure 4. ADAMTS8 is a functional TSG that inhibits clonogenicity and induces apoptosis of tumor cells. A, protein structure of ADAMTS8metalloproteasewith
different domains as illustrated: SS, signal sequence; Pro, prodomain; MP, metalloprotease domain; Dis, disintegrom domain; Cys, ADAM cysteine-rich
domain; SP, spacer domain; and TSP-1, thrombospondin type 1 repeats. B, confocal microscopy assay showed that ADAMTS8 (green) was localized at cell
membrane in ADAMTS8-transfected HONE1 cells. DAPI counterstaining (blue) was used to visualize DNA. Original magniﬁcation, 400. C, the detection of
ADAMTS8 protein by Western blot analysis in both cell lysate and media. Culturing media were collected from ADAMTS8- or vector-transfected
KYSE150 cells for 24 hours. Cell lysate was collected at 48 hours after transfection. D, representative colony formation assay with monolayer culture (left).
Ectopic ADAMTS8 expression in tumor cells was conﬁrmed by Western Blot analysis (right, upper). Quantitative analysis of colony formation ability in
ADAMTS8-transfected cells (right, lower). The number of G418-resistant colonies in each vector-transfected cells was set as 100 (, P < 0.05). E, the
proapoptotic effect of ADAMTS8 in both HONE1 and KYSE150 cells was assessed by TUNEL assay (left). TUNEL-positive cells (green) are counted
as apoptotic cells. Western blot analysis showing upregulation of cleaved PARP in ADAMTS8-transfected tumor cells (right).
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ADAMTS8 suppresses cell migration by disrupting stress
ﬁber formation
As EGFR–MEK–ERK signaling activation is implicated
in actin cytoskeletal reorganization and cell migration, the
role of ADAMTS8 on actin ﬁlament integrity and tumor cell
motility was further investigated. Results showed that actin
stress ﬁbers were disassembled in ADAMTS8-expressing
HONE1 cells, but not in control cells (Fig. 6A). Cell
motility of ADAMTS8-transfected KYSE150 cells displayed
a marked delay in wound closure compared with controls, as
measured by wound-healing assay (Fig. 6B), suggesting that
ADAMTS8 inhibits migration of tumor cells via disrupting
stress ﬁlament integrity.
Discussion
In this work, we found that ADAMTS8 is frequently
silenced in multiple carcinoma cell lines but broadly
expressed in human normal adult and fetal tissues. Promoter
methylation seems to be a major mechanism inactivating
ADAMTS8, although genetic alterations or histone mod-
iﬁcations may also be involved. We also found that
ADAMTS8 functions as a proapoptotic tumor suppressor
through antagonizing EGFR–MEK–ERK signaling, further
suppresses tumor cells migration through disrupting stress
ﬁber formation (Fig. 6C).
Although as demonstrated here and in other studies,
ADAMTS8 is downregulated in multiple cancers, few stud-
ies have reported about its function and related mechanism
in tumorigenesis. Our study seems to be the ﬁrst to reveal
that ADAMTS8 possesses antitumor properties and its
underlying mechanism besides previously reported role in
anti-angiogenesis. We found that ADAMTS8 metallopro-
tease exerts tumor suppressive functions by inhibiting tumor
cell clonogenicity, eliciting apoptosis, and restraining tumor
cell migration. As apoptotic property has not been reported
for ADAMTS members, this study indicates the possibility
that other ADAMTS members may also involve in the
regulation of apoptosis.We further found that the inhibition
of tumor cell growth and induction of apoptosis by
ADAMTS8 are associated with deregulation of EGFR–
MEK–ERK signaling pathway, and secreted ADAMTS8
also exhibits inhibitory effect on EGFR signaling, in line
with the ﬁndings in ADAMTS1 and ADAMTS15, another
2 members of the same subgroup (4, 33). Thus, we report
here that ADAMTS8 is another ADAMTS member dis-
playing antitumorigenic (4, 33, 34).
It is intriguing that ADAM and ADAMTS members are
often observed to possess opposing roles in tumorigenesis
and the modulation of EGFR-ERK signaling, although they
both belong to the metzincin-superfamily of Zinc-depen-
dent metalloproteinases (35). Proteolytic function of
ADAMTS8 as an aggrecanase was demonstrated previously
(36). The TSP-1 domain present in ADAMTSmembers but
absent in ADAM group is responsible for this opposite
behavior (7). Ectopic expression of TSP-1 was shown to
block MAPK signaling activation and slow down tumor
formation (37), whereas cells with mutated form of
Figure 5. Secreted ADAMTS8
inhibits EGFR–MEK–ERK
signaling. A, Western blot analysis
of phosphorylated EGFR and total
EGFR in both ADAMTS8-
expressing KYSE150 cell lysate
and cells treated with CM
containing ADAMTS8 for 24 hours.
B, phosphorylated MEK, ERK, and
total ERK as measured by Western
blot analysis in ADAMTS8 or
vector-transfected HONE1 and
KYSE150cells.C,D,SREandAP-1
luciferase reporter activity assays
in vector- and ADAMTS8-
expressing tumor cells. Cells were
cotransfected with either vector or
ADAMTS8, together with pSRE-
Luc or pAP-1 reporter plasmids
and renilla reporter plasmid. The
activity of luciferase was
normalized with the renilla activity.
Data shown are means  SE of
triplicate transfections in 3
independent experiments. Asterisk
indicates statistically signiﬁcant
difference (, P < 0.05).
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ADAMTS15 lacking 2 TSP-1 motifs had elevated ERK
phosphorylation level compared with cells harboring wild-
type ADAMTS15 (4). In addition, TSP-1 in auto-proteo-
lytic cleaved ADAMTS1 is required for inhibiting ERK (2).
Therefore, the TSP-1 domain in ADAMTS members is
likely involved in suppressing the activated MEK-ERK
signaling in cancer cells.
Most metalloproteinases are regarded as key regulators
of tumor cell invasiveness, because they possess proteolytic
activities to destruct the ECM and alter the cell–cell
attachments and cell–matrix attachments, which are inte-
gral to tumor cell migration (38). However, little is known
about the involvement of ADAMTS members in cell
invasion except for ADAMTS1 and ADAMTS5. Full-
length ADAMTS1 and ADAMTS5 are reported to pro-
mote metastasis whereas fragment of ADAMTS1 was
shown to be antimetastatic (2, 39). Here, we also iden-
tiﬁed that ADAMTS8 suppressed tumor cell migration by
disrupting actin polymerization. Further study of
ADAMTS8 on cell epithelial–mesenchymal transition is
needed.
In summary, our study shows that ADAMTS8 func-
tions as a proapoptotic TSG through suppressing EGFR–
MEK–ERK signaling, which is frequently silenced by
promoter CpG methylation in common carcinomas.
However, further investigations are needed to show exact
feature and function of ADAMTS8 in connection to
cellular homeostasis.
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